Early-Onset Alzheimer’s Disease Masquerading as Catatonia
Table 1
Laboratory tests performed.
Test
Result
Initial testing
Complete metabolic panel and liver function tests
Within normal limits
Complete blood count
Within normal limits
Urine analysis
Within normal limits
Thyroid-stimulating hormone
0.97 (0.27–4.20) uIU/mL
Chest X-ray
Unremarkable
Urine toxicology
Amphetamines screen: negative
Barbiturates screen: negative
Cocaine screen: negative
Benzodiazepine screen: negative
THC screen: negative
Methadone: negative
Oxycodone screen: negative
Opiates screen: negative
Phencyclidine screen: negative
Secondary workup
HIV 1/2 rapid antibody
Nonreactive
Rapid plasma reagin
Negative
Sedimentation rate
10 (0–20) mm/hr
C-reactive protein
<0.03 (<0.5) mg/dL
Autoimmune panel
Antinuclear antibody: negative
Antineutrophil cytoplasmic Ab: negative
C4, 29 (10–40) mg/dL
C3, 139 (90–180) mg/dL
SSA Ab <0.3 (0.0–6.9) U/mL
SSB Ab <0.3 (0.0–6.9) U/mL
Anti-DSDNA 7 (0–24) IU
Smith antibody 1.5 (0.0–6.9) U/mL
Anti-TPO: negative
Mayo dementia, autoimmune evaluation panel: negative
Cerebrospinal fluid studies
Color and clarity
Clear and colorless
White blood cells
1 (0–10) mm3
Red blood cell count
1 mm3
Protein
19 (15–45) mg/dL
Glucose
64 (40–70) mg/dL
Myelin basic protein
Negative
Oligoclonal bands
Negative
Cytology
No atypical lymphoid cells
Mayo paraneoplastic panel
Negative
Mayo dementia, autoimmune evaluation panel
Negative
Protein 14-3-3
<0.2
Neuronal specific enolase
Negative
VDRL
Negative
We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.